Aflibercept

From Self-sufficiency
Jump to: navigation, search
Aflibercept
Systematic (IUPAC) name
Unable to be assigned
Identifiers
CAS Number 862111-32-8
ATC code none
Chemical data
Formula C4318H6788N1164O1304S32
Molar mass 96.90 kDa[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Aflibercept is a fusion protein under development for the treatment of cancer.

It functions as an inhibitor of vascular endothelial growth factor.[1][2]

Aflibercept is being co-developed by Sanofi-Aventis and Regeneron Pharmaceuticals. As of 2008, it is currently in phase III clinical trials.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
CI monoclonal antibodies ("-mab")
Others for solid tumors
Tyrosine kinase inhibitors ("-nib")
Other
fusion protein against VEGF (Aflibercept) · exotoxin against IL-2 (Denileukin diftitox)
Intracellular
(initiation)
Macrolides/
other IL-2 inhibitors
TNF-α inhibitor
Intracellular
(reception)
Extracellular
Serum target
(noncellular)
Cellular target
Unsorted
-cept (Fusion)


40px This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it.
  1. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Aflibercept&oldid=23430"